Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05334693
PHASE1/PHASE2

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Sponsor: Belarusian Research Center for Pediatric Oncology, Hematology and Immunology

View on ClinicalTrials.gov

Summary

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.

Official title: Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Key Details

Gender

All

Age Range

6 Months - 21 Years

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2021-11-01

Completion Date

2026-06

Last Updated

2024-08-28

Healthy Volunteers

No

Interventions

BIOLOGICAL

Expanded haploidentical NK cells

Two doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).

Locations (1)

Belarussian Research Center for Pediatric Oncology, Hematology and Immunology

Minsk, Minsk Oblast, Belarus